JNJ-77242113 Study Initiated for Moderate to Severe Plaque Psoriasis
A clinical trial has been initiated to evaluate the efficacy of JNJ-77242113 in treating moderate to severe plaque psoriasis.
Company
Pharmaceutical intelligence for JNJ-77242113 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.